|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.13 USD | +0.27% |
|
-.--% | - |
| 25-07-27 | Verve Therapeutics, Inc.(NasdaqGS:VERV) dropped from S&P Biotechnology Select Industry Index | CI |
| 25-07-27 | Verve Therapeutics, Inc.(NasdaqGS:VERV) dropped from S&P Global BMI Index | CI |
Company Valuation: VERE THER
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Market Cap 1 | 1,776 | 1,192 | 1,095 | 477.5 |
| Change | - | -32.88% | -8.14% | -56.39% |
| Enterprise Value (EV) 1 | 1,418 | 719.1 | 545.9 | 23.21 |
| Change | - | -49.27% | -24.09% | -95.75% |
| P/E | -8.23x | -6.64x | -4.47x | -2.4x |
| PBR | 5.01x | 2.17x | 1.91x | 1.01x |
| PEG | 0.1x | 0.2x | -0.64x | 0.1x |
| Capitalization / Revenue | - | 614,133,589x | 93,125,869x | 14,768,776x |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -16.6x | -4.42x | -2.51x | -0.1x |
| EV / EBIT | -16.3x | -4.34x | -2.45x | -0.1x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -4.477 | -2.913 | -3.118 | -2.345 |
| Distribution rate | - | - | - | - |
| Net sales | - | 1.941 | 11.76 | 32.33 |
| EBITDA 1 | -85.53 | -162.9 | -217.7 | -221.9 |
| EBIT 1 | -87.07 | -165.7 | -223.1 | -228.7 |
| Net income 1 | -120.3 | -157.4 | -200.1 | -198.7 |
| Net Debt 1 | -358.5 | -472.9 | -549 | -454.3 |
| Reference price 2 | 36.87 | 19.35 | 13.94 | 5.64 |
| Nbr of stocks (in thousands) | 48,171 | 61,604 | 78,549 | 84,664 |
| Announcement Date | 3/14/22 | 3/2/23 | 2/27/24 | 2/27/25 |
1USD in Million2USD
Estimates
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VERV Stock
- Valuation VERE THER
Select your edition
All financial news and data tailored to specific country editions
